POPULATION-BASED BIOINFORMATIC CHARACTERIZATION OF VKORC1 GENE VARIANTS INFLUENCING WARFARIN SENSITIVITY-A DESCRIPTIVE STUDY

POPULATION-BASED BIOINFORMATIC CHARACTERIZATION OF VKORC1 GENE VARIANTS INFLUENCING WARFARIN SENSITIVITY-A DESCRIPTIVE STUDY

C. N. Ramya Murthy and K. G. Satheesh Kumar *

Department of Pharmacology, Sri Venkateshwara Medical College, Tirupati, Andhra Pradesh, India.

ABSTRACT: Background: Warfarin dosing varies greatly between individuals and across populations, and much of this variation is driven by polymorphisms in the VKORC1 gene. Understanding how these variants influence gene expression and function is crucial for improving dose accuracy and preventing complications. Objective: To characterise key VKORC1 variants using an in-silico approach and to assess how their predicted functional effects and population frequencies contribute to global differences in warfarin sensitivity. Methods: Genomic data from gnomAD and the 1000 Genomes Project were analysed to examine major VKORC1 variants across South Asian, European, and East Asian populations. Functional and regulatory impacts were predicted using SIFT, PolyPhen-2, PROVEAN, ConSurf, JASPAR, and RegulomeDB. Genotype frequencies were estimated using the Hardy–Weinberg model and interpreted in relation to expected warfarin dosing categories, including sensitive, intermediate, and normal-dose groups. Results: The promoter variant rs9923231 and intronic variant rs9934438, both linked to reduced VKORC1 expression and lower warfarin dose requirements, were most frequent in East Asians (around 80–90%). The 3′UTR variant rs7294, associated with higher gene activity and increased dose needs, was predominantly seen in South Asians (~69%). The rare coding variant rs61742245 (Asp36Tyr), predicted to cause major structural disruption and warfarin resistance, occurred at less than 0.1%. Overall, East Asians showed more sensitivity-linked genotypes, Europeans displayed mixed patterns, and South Asians carried more resistance-associated variants. Conclusion: VKORC1 variability significantly shapes inter-ethnic warfarin dose differences. Incorporating these variants into population-tailored dosing strategies may improve the safety and precision of anticoagulation therapy.

Keywords: VKORC1 polymorphisms, Warfarin sensitivity, Pharmacogenomics, Population genetics, In-silico analysis

INTRODUCTION: Warfarin remains a widely used anticoagulant for preventing and treating thromboembolic disorders, yet its clinical use is complicated by a narrow therapeutic window and marked inter-individual dose variability ¹. The enzyme encoded by the VKORC1 gene (vitamin K epoxide reductase complex subunit 1) is the pharmacologic target of warfarin, and genetic variation within this gene has been shown to significantly influence sensitivity to warfarin, thereby altering both dose requirement and bleeding risk ^{2, 3}.

In diverse ethnic groups including Middle Eastern, South Asian and Latin American cohorts studies have demonstrated that common polymorphisms of VKORC1 (such as -1639G>A or rs9923231) are strongly associated with reduced warfarin dose requirement, thereby contributing to dose variability at a population level ^{4, 5, 6}. However, the functional impact of many VKORC1 variants particularly rare, regulatory, or population-specific alleles remains poorly characterised. Most previous research has focused on a small set of common polymorphisms, leaving important gaps in understanding how diverse VKORC1 sequence changes may affect gene regulation, protein structure, and ultimately, warfarin sensitivity.

Bioinformatic approaches offer a practical and scalable way to address these gaps. In-silico tools allow researchers to explore evolutionary conservation, structural changes, and regulatory effects, giving early indications of how a variant might influence VKORC1 function even before clinical studies are performed ⁷. However, only a limited number of investigations have combined these functional predictions with population-level allele frequency data, which is essential for understanding global differences in warfarin response. This study therefore conducts a systematic in-silico characterisation of both common and rare VKORC1 variants across major populations. By linking predicted functional effects with population distributions, the study aims to enhance understanding of VKORC1-driven variability in warfarin sensitivity and support more precise, population-tailored dosing strategies.

METHODOLOGY:

Data Sources: Publicly available genomic datasets were used for this in-silico analysis. Allele frequency data for VKORC1 variants were obtained from the Genome Aggregation Database (gnomAD v2.1.1) and the 1000 Genomes Project Phase 3. Three major global populations were evaluated: South Asians (SAS), Europeans (EUR), and East Asians (EAS), selected due to known differences in warfarin response and VKORC1 variant distribution. As only secondary datasets and computational tools were utilised, no ethical approval was required. Variant Selection: VKORC1 variants were included if allele frequency data were available in at least one selected population. Functionally relevant promoter, intronic, 3′UTR, regulatory, coding, and intergenic variants commonly implicated in warfarin pharmacogenomics were prioritised. The final panel included: rs9923231 (promoter), rs9934438 (intronic), rs7294 (3′UTR), rs17708472 (regulatory), rs61742245 (missense; Asp36Tyr), rs17878544 (intergenic regulatory).

Functional Prediction Tools: SIFT (v6.2.1), Database: UniProt + Ensembl protein sequences, Output: SIFT score (0–1), Threshold: ≤0.05 = deleterious, >0.05 = tolerated. PolyPhen-2 (version 2.2.2), Models used: HumDiv and HumVar, Output categories: Probably damaging (score >0.85), Possibly damaging (0.15–0.85), Benign (<0.15) PROVEAN (v1.1.5), Database: NCBI NR protein database with BLAST-based clustering, Threshold: ≤ −2.5 = deleterious, > −2.5 = neutral ConSurf (Server v1.0, 2024 release), Algorithm: Bayesian inference using a multiple sequence alignment of homologs, Scoring: 1–9 conservation scale (1 = variable, 9 = highly conserved) JASPAR (2024 Core Vertebrate Database), Approach: Position Frequency Matrix (PFM)–based transcription factor binding site prediction, Output: Predicted gain/loss of TF motifs; relative score threshold ≥80% used for reporting RegulomeDB (v2.0.3), Integrates: ENCODE, ChIP-seq, DNase-seq, ATAC-seq, TF motifs, Score interpretation:1a–1f: likely regulatory with strong evidence, 2a–2c: likely regulatory, 3–6: minimal to no evidence

Genotype counts Table 4 were estimated using Hardy–Weinberg equilibrium (HWE) with a hypothetical population of n = 1000 for proportional representation of alleles. This approach standardizes comparisons across populations, reflecting relative allele frequencies while enabling visualization of predicted warfarin sensitivity and resistance.

Population Analysis: Allele frequencies for each variant were extracted for SAS, EUR, and EAS populations. Expected genotype frequencies were calculated using Hardy–Weinberg Equilibrium (HWE) proportions (p², 2pq, q²).

Genotype distributions were mapped to predicted warfarin-response categories: AA = sensitivity / low-dose requirement, AA = intermediate sensitivity, aa = normal-dose phenotype.

Data Processing: All computations and tabulations were performed in Microsoft Excel (Microsoft Office 2021). Functional predictions were manually integrated with population-frequency data to infer variant-level contributions to warfarin dose variability.

Work Flow:

RESULTS:

TABLE 1: STRUCTURAL AND FUNCTIONAL PREDICTION OF VKORC1 VARIANTS

Table 1 shows the structural and functional effects of major VKORC1 SNPs based on in-silico prediction tools. Among all variants, only the missense SNP rs61742245 showed a strong deleterious effect, supported by all protein-prediction tools and high evolutionary conservation, indicating a potential to cause warfarin resistance. The common regulatory variants (rs9923231, rs9934438, rs7294) did not affect protein structure but showed clear transcriptional or post-transcriptional effects.

TABLE 2: REGULATORY VARIANT ANALYSIS OF VKORC1 PROMOTER AND NONCODING SNPS

Table 2 shows the predicted transcription factor binding alterations and regulatory consequences of VKORC1 noncoding SNPs. rs9923231 demonstrated the strongest regulatory influence, with predicted loss of activator binding and reduced VKORC1 expression, consistent with increased warfarin sensitivity. rs9934438 behaved mainly as a linked marker. rs7294 showed potential disruption of miRNA binding, suggesting higher VKORC1 expression and reduced sensitivity. Other regulatory variants showed minimal predicted effects.

TABLE 3: ALLELE FREQUENCY OF VKORC1 VARIANTS ACROSS POPULATIONS

Table 3 shows substantial population-level differences in allele frequencies for major VKORC1 variants. Large interethnic variation was evident. Sensitivity-associated alleles (rs9923231 A, rs9934438 T) were most frequent in East Asians, moderate in Europeans, and least common in South Asians. The resistance-associated rs7294 A allele showed the opposite trend. Rare variants remained uniformly uncommon across populations.

TABLE 4: PREDICTED PHARMACOGENOMIC IMPACT OF VKORC1 GENOTYPES ON WARFARIN DOSE

Table 4 shows clear population-level differences in the pharmacogenomic impact of VKORC1 variants on warfarin dosing. Genotype distributions reflected these frequencies: East Asians showed predominantly sensitivity genotypes, Europeans showed mixed profiles, and South Asians carried more resistance-associated genotypes. Overall, the results reinforce that VKORC1 regulatory variants especially rs9923231 are key drivers of population-specific warfarin dose requirements.

TABLE 5: SUMMARY OF PHARMACOGENOMIC SIGNIFICANCE OF VKORC1 VARIANTS

Table 5 shows a consolidated summary of the functional significance of each VKORC1 variant. Collectively, the results demonstrate that VKORC1 regulatory variants particularly rs9923231 and rs9934438 drive warfarin sensitivity, whereas rs7294 contributes to resistance, with strong ethnic stratification shaping population-specific dose needs. The in-silico findings support the integration of VKORC1 genotypes in precision dosing frameworks and highlight the importance of population genomics in warfarin therapy.

DISCUSSION: This in-silico analysis reinforces that VKORC1 polymorphisms are key determinants of warfarin dose variability across populations ^{7, 8}. The promoter variant rs9923231 (−1639G>A) remains the most clinically relevant, with the G→A substitution disrupting HNF4α binding and enhancing GATA2 binding, reducing VKORC1 expression and increasing warfarin sensitivity ⁹. As expected, East Asians carry this allele at >80%, explaining their lower dose requirements compared to Europeans and South Asians ¹⁰.

The intronic variant rs9934438 (1173C>T), which is closely linked to rs9923231, serves as a haplotype tag and indirectly influences VKORC1 expression through enhancer and splicing mechanisms. European studies have confirmed that individuals with this variant are more sensitive to warfarin ¹¹^, ¹², supporting its inclusion in CPIC dosing guidelines ¹³.

In contrast, the rs7294 (3′UTR G>A) variant exerts the opposite pharmacogenomic effect. The substitution of guanine by adenine enhances mRNA stability by altering miRNA binding motifs (such as miR-133a and miR-137), resulting in increased VKORC1 protein levels and reduced warfarin efficacy. Population-based studies from South and Central Asia demonstrate that the rs7294 A allele reaches frequencies as high as 70% in South Asians and up to 60% in Middle Eastern populations, accounting for their greater average dose requirements ¹⁴. Simulation results from this study also indicated that carriers of the A allele may require up to 20–30% higher warfarin doses to achieve therapeutic INR, consistent with reports from Indian, Pakistani, and Bulgarian cohorts ¹⁵.

The rare coding variant rs61742245 (Asp36Tyr), though present in less than 0.1% of individuals globally, disrupts VKORC1 structure and contributes to warfarin resistance, consistent with clinical observations ⁸. Minor variants such as rs17708472 and rs17878544 have limited functional effects but could influence response when occurring alongside high-impact alleles ¹². However, their presence in certain haplotypes suggests a potential modulatory role when combined with high-impact alleles, a hypothesis warranting further molecular investigation. Taken together, these variants show a clear ethnic gradient: East Asians mainly carry sensitivity alleles, Europeans display intermediate frequencies, and South Asians are enriched for resistance alleles ¹³^, ¹⁴. These patterns emphasize the importance of population-specific VKORC1 genotyping for personalized anticoagulation, ideally combined with CYP2C9 and CYP4F2 genotypes, and point to the potential of machine learning models to further refine individualized warfarin dosing ⁸^, ¹⁵. Understanding this genetic diversity can help achieve safer and more effective therapy across different populations.

Strengths and Limitations: A major strength of this study is its comprehensive integration of multiple bioinformatic tools (SIFT, PolyPhen-2, PROVEAN, ConSurf, JASPAR, and RegulomeDB), enabling a multi-dimensional evaluation of both coding and noncoding VKORC1 variants. The use of large-scale genomic data from gnomAD and the 1000 Genomes Project provided robust cross-population comparisons.

However, limitations include the absence of clinical validation and reliance on in-silico predictions, which may not fully capture the complexity of in-vivo gene regulation and pharmacodynamics. Furthermore, rare variants with uncertain significance warrant functional assays to confirm predicted effects.

CONCLUSION: This study highlights the significant impact of VKORC1 genetic variants on warfarin response, emphasizing that differences in rs9923231, rs9934438, and rs7294 largely explain inter-individual and inter-ethnic variability in dose requirements. Sensitivity-associated variants, particularly rs9923231 and rs9934438, were most prevalent in East Asians, while rs7294, linked to increased VKORC1 activity, was common in South Asians, accounting for their higher average dose needs. Rare coding variants such as rs61742245 had strong functional effects but limited population-level influence, and minor variants showed minimal impact. These findings underscore the importance of population-specific genotyping in guiding warfarin dosing. Combining bioinformatic predictions with clinical data can enhance therapeutic safety, reduce adverse events, and support more personalized anticoagulation strategies, advancing precision medicine in pharmacogenomics.

ACKNOWLEDGEMENT: Nil

Funding: Nil

CONFLICT OF INTEREST: Nil

REFERENCES:

1. Holail J, Mobarak R, Al-Ghamdi B, Aljada A and Fakhoury H: Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. Drug Metab Pers Ther 2022. doi: 10.1515/dmdi-2022-0108. Epub ahead of print. PMID: 35365981
2. Radhi, Ayoob, Aziz and Hussam: The Role of VKORC1 in Vitamin K Metabolism and Warfarin Sensitivity: A Narrative Review of Genetic and Clinical Perspectives. OBAT Jurnal Riset Ilmu Farmasi dan Kesehatan 2025; 3: 287-299. 10.61132/obat.v3i5.1697.
3. Sundari, Ankani, Syamala D & Sivaraj R & G, Somasundaram and Codi R: Impact of cyp2c9 and vkorc1 genetic variants on warfarin therapy optimization in south indian population with venous thromboembolism. Journal of Population Therapeutics and Clinical Pharmacology 2025. 10.53555/2f8rtf51.
4. Fahmi AM, Elewa H and El Jilany I: Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. International Journal of Clinical Pharmacy 2022; 44.
5. HS: Novel Gene Polymorphisms for Stable Warfarin Dose in a Korean Population: Genome-Wide Association Study. Biomedicines 2023; 11(8): 2308. doi: 10.3390/biomedicines11082308. Erratum in: Biomedicines 2025; 13(5): 1238. doi: 10.3390/biomedicines13051238. PMID: 37626805; PMCID: PMC10452379.
6. Oscanoa TJ, Guevara-Fujita ML, Fujita RM, Muñoz-Paredes MY, Acosta O and Romero-Ortuño R: Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients. Br J Clin Pharmacol 2024; 90(3): 769-775. doi: 10.1111/bcp.15958. Epub 2023 Nov 24. PMID: 37940132.
7. Bagher AM, Alharbi W, Gadi LS, Binmahfouz LS and Hareeri RH: Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population. Journal of Pharmacology and Pharmacotherapeutics 2023.
8. Fülöp P, Tóth Š, Porubän T, Fülöpová Z, Borovská A and Dvorožňáková M: Machine Learning for Warfarin Therapy: A Systematic Review. Pharmaceuticals 2025; 18(10): 1544.
9. Tzveova R, Saraeva R, Dimitrova-Karamfilova A, Nachev G, Mitev V and Kaneva R: Establishment of Acenocoumarol Pharmacogenetic Algorithm Including CYP2C9 and VKORC1 Genotypes in Bulgarian Patients Treated with Coumarin Anticoagulants. Acta Medica Bulgarica 2025; 52(2): 12–23.
10. Abouelhoda M, Almuqati N, Abogosh A, Alfraih F, Maddirevula S and Alkuraya FS: Mining local exome and HLA data to characterize pharmacogenetic variants in Saudi Arabia. Human Genetics 2023; 143(2): 125–36.
11. Рени Цвеова, Dimitrova-Karamfilova A, Vandeva S, Atanasov P, Pendicheva-Duhlenska D and Nachev G: Polymorphic variants in acenocoumarol-related genes CYP2C9 and VKORC1 and their frequencies in Bulgarian population. Acta Medica Bulgarica 2025; 52(3): 22–31.
12. Maleki O and Javad Gharechahi: Association of VKORC1 and CYP2C9 gene polymorphisms with warfarin dose requirements in a representative Iranian population with cardiac valve replacement surgery. Pharmacogenetics and Genomics 2025; 35(7): 214–20.
13. Muyambo S, Ndadza A, Soko ND, Kruger B, Kadzirange G and Chimusa E: Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. OMICS: a Journal of Integrative Biology 2022; 26(1): 35–50.
14. Khan AR, Shah SH, Ajaz S, Firasat S, Abid A and Raza A: The prevalence of pharmacogenomics variants and their clinical relevance among the Pakistani population. Evolutionary Bioinformatics 2022; 18.
15. Sahana S, Bhoyar RC, Ambily Sivadas, Jain A, Imran M and Rophina M: Pharmacogenomic landscape of Indian population using whole genomes. Clinical and Translational Science 2022; 15(4): 866–77.
    

    ---

    How to cite this article:

    Murthy CNR and Kumar KGS: “Population-based bioinformatic characterization of vkorc1 gene variants influencing warfarin sensitivity-a descriptive study”. Int J Pharm Sci & Res 2026; 17(4): 1226-33. doi: 10.13040/IJPSR.0975-8232.17(4).1226-33.

    ---

    All © 2026 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.